Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews.
bleeding
complications
haemarthrosis
health-related quality of life
healthcare costs
von Willebrand disease
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
07
04
2022
received:
17
11
2021
accepted:
26
08
2022
pubmed:
13
9
2022
medline:
21
3
2023
entrez:
12
9
2022
Statut:
ppublish
Résumé
Debilitating clinical complications in von Willebrand disease (VWD) can affect health-related quality of life (HRQoL), increase healthcare costs and cause long-lasting consequences. However, the magnitude of these burdens needs to be more fully explored. To estimate the prevalence and burden of clinical complications, the impact on HRQoL and the economic burden associated with VWD. Embase Among 16 studies assessing clinical complications in VWD, the most prevalent bleeding symptoms were menorrhagia (2%-95% [n = 7 studies]), epistaxis (12%-80% [n = 6]) and easy bruising (46%-65% [n = 2]). Among 17 studies evaluating HRQoL, the most common assessment scales were the generic SF-36 (n = 8 studies) and the EQ-5D (n = 2). Bleeding symptoms were associated with reduced QoL in six of seven studies, and of six studies evaluating treatment impact, four reported improvements in one or more HRQoL components. Among 25 studies on cost and resource use, key observations included higher post-surgery healthcare costs in VWD versus non-VWD patients (n = 1 study) and higher costs and resource use in VWD patients with bleeding complications versus those without (n = 1). Although limited, available evidence suggests that VWD patients experience a high burden of clinical complications, reduced QoL and high healthcare costs. Haemarthrosis is more common in severe VWD than is often assumed, and bleeds (including haemarthrosis) can reduce QoL. Research efforts to improve QoL and other outcomes should be prioritized.
Substances chimiques
von Willebrand Factor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-422Subventions
Organisme : CSL Behring
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Leebeek FW, Eikenboom JC. von Willebrand's disease. N Engl J Med. 2016;375(21):2067-2080.
de Wee EM, Fijnvandraat K, de Goede-Bolder A, et al. Impact of von Willebrand disease on health-related quality of life in a pediatric population. J Thromb Haemost. 2011;9(3):502-509.
Castaman G, Goodeve A, Eikenboom J. European Group on von Willebrand D. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667-674.
De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost. 2016;14(3):449-460.
Federici AB. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol. 2016;38(Suppl 1):41-49.
Miesbach W, Berntorp E. Translating the success of prophylaxis in haemophilia to von Willebrand disease. Thromb Res. 2021;199:67-74.
Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. J Manag Care Spec Pharm. 2021;27(2):175-185.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-898.
Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213-216.
Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325.
van Galen KP, Sanders YV, Vojinovic U, et al. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015;21(3):e185-e192.
Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs. 2017;77(14):1531-1547.
Karimi M, Health BrazierJ. Health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34(7):645-649.
SBU. Treatment of Hemophilia A and B and von Willebrand disease. Swedish Council on Health Technology Assessment SBU report no 208E. 2012.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269. W264.
Tsagianni A, Comer DM, Yabes JG, Ragni MV. Von Willebrand disease and gastrointestinal bleeding: a national inpatient sample study. Thromb Res. 2019;178:119-123.
Apostolova MH, Seaman CD, Comer DM, Yabes JG, Ragni MV. Prevalence and risk factors associated with hypertension in von Willebrand disease. Clin Appl Thromb Hemost. 2018;24(1):93-99.
James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165-1169.
Sanders YV, Eikenboom J, de Wee EM, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost. 2013;11(5):845-854.
Tosetto A, Badiee Z, Baghaipour MR, et al. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost. 2020;18(9):2145-2154.
Alesci RS, Krekeler S, Seifried E, Miesbach W. Do patients with haemophilia and von Willebrand disease with arterial hypertension have bleeding complications: a German single centre cohort. Blood Coagul Fibrinolysis. 2012;23(4):320-323.
Metjian AD, Wang C, Sood SL, et al. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 2009;15(4):918-925.
Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia. 2003;9(3):292-297.
Mohsin S, Aslam M, Hussain S, Suhail S. Clinical manifestations and complications of von Willebrand disease. J Rawalpindi Med Coll. 2012;16(1):19-21.
Abe K, Dupervil B, O'Brien SH, et al. Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease. Am J Hematol. 2020;95(1):10-17.
Rae C, Furlong W, Horsman J, et al. Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life. Haemophilia. 2013;19(3):385-391.
Byams VR, Kouides PA, Kulkarni R, et al. Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia. 2011;17(Suppl 1):6-13.
Xu Y, Deforest M, Grabell J, Hopman W, James P. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017;23(1):115-121.
Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6(6):643-648.
Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia. 2001;7(1):53-63.
Govorov I, Ekelund L, Chaireti R, et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's disease. Exp Ther Med. 2016;11(5):1923-1929.
Barg K, Wiewiorski M, Anderson AE, et al. Total ankle replacement in patients with von Willebrand disease: mid-term results of 18 procedures. Haemophilia. 2015;21(5):e389-e401.
Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004;111(12):1425-1428.
Sidonio RF, Haley KM, Fallaize D. Impact of diagnosis of von Willebrand disease on patient outcomes: analysis of medical insurance claims data. Haemophilia. 2017;23(5):743-749.
Allen GC, Armfield DR, Bontempo FA, Kingsley LA, Goldstein NA, Post JC. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg. 1999;125(5):547-551.
Oladapo A, Wu Y, Lu M, Farahbakhshian S, Ewenstein B. Economic burden associated with major surgery in patients with von Willebrand disease: a United States retrospective administrative database analysis. J Blood Med. 2021;12:699-708.
James AH, Myers ER, Cook C, Pietrobon R. Complications of hysterectomy in women with von Willebrand disease. Haemophilia. 2009;15(4):926-931.
Fogarty PF, Blair A, Vega R, Matthai WH, Gimotty PA. Interventional therapies and in-hospital outcomes in acute coronary syndromes complicated by von Willebrand disease. Haemophilia. 2017;23(3):400-407.
Miners AH, Sabin CA, Tolley KH, Lee CA. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia. 1998;4(1):4-9.
Castaman G, Coppola A, Zanon E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia. 2013;19(1):82-88.
Holm E, Carlsson KS, Lovdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia. 2018;24(4):628-633.
Ramstrom G, Blomback M, Egberg N, Johnsson H, Ljungberg B, Schulman S. Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int J Oral Maxillofac Surg. 1989;18(6):320-322.
Peyvandi F, Castaman G, Gresele P, et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17(5):391-398.
Carcao MD, Seary ME, Casas M, Winter L, Stain AM, Judd P. Dental disease in type 3 von Willebrand disease: a neglected problem. Haemophilia. 2010;16(6):943-948.
Schinco P, Cultrera D, Valeri F, et al. Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context. Clinicoecon Outcomes Res. 2015;7:17-25.
Dye DE, Brameld KJ, Maxwell S, et al. The impact of single gene and chromosomal disorders on hospital admissions of children and adolescents: a population-based study. Public Health Genomics. 2011;14(3):153-161.
Sidonio RF Jr, Smith KJ, Ragni MV. Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia. J Pediatr. 2010;157(3):456-460.
Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia. 2013;19(1):21-26.
de Wee EM, Sanders YV, Mauser-Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108(4):683-692.
Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111(4):1236-1239.
van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost. 2018;118(10):1690-1700.
Sood SL, Cuker A, Wang C, et al. Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia. 2013;19(4):595-601.
Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1-159.
van Galen KPM, de Kleijn P, Foppen W, et al. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica. 2017;102(9):1486-1493.
van Galen KPM, Meijer K, Vogely HC, et al. Joint surgery in von Willebrand disease: a multicentre cross-sectional study. Haemophilia. 2016;22(2):256-262.
Abshire T, Cox-Gill J, Kempton CL, et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. J Thromb Haemost. 2015;13(9):1585-1589.
Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015;26(4):383-388.
Connell NT, James PD, Brignardello-Petersen R, et al. von Willebrand disease: proposing definitions for future research. Blood Adv. 2021;5(2):565-569.